nach oben

Virchows Archiv

Erschienen in:

01.04.2014 | Review and Perspectives

Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care

verfasst von: John D. Hainsworth, F. Anthony Greco

Erschienen in: Virchows Archiv | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Carcinoma of unknown primary site (CUP) is diagnosed in approximately 3 % of patients with advanced cancer, and most patients have traditionally been treated with empiric chemotherapy. As treatments improve and become more specific for individual solid tumor types, therapy with a single empiric combination chemotherapy regimen becomes increasingly inadequate. Gene expression profiling (GEP) is a new diagnostic method that allows prediction of the site of tumor origin based on gene expression patterns retained from the normal tissues of origin. In blinded studies in tumors of known origin, GEP assays correctly identified the site of origin in 85 % of cases and compares favorably with immunohistochemical (IHC) staining. In patients with CUP, GEP is able to predict a site of origin in >95 % of patients versus 35–55 % for IHC staining. Although confirmation of the accuracy of these predictions is difficult, the diagnoses made by IHC staining and GEP are identical in 77 % of cases when IHC staining predicts a single primary site. GEP diagnoses appear to be most useful when IHC staining is inconclusive. Site-specific treatment of CUP patients based on GEP and/or IHC predictions appears to improve overall outcomes; patients predicted to have treatment-sensitive tumor types derived the most benefit. GEP adds to the diagnostic evaluation of patients with CUP and should be included when IHC staining is unable to predict a single site of origin. Site-specific treatment, based on tissue of origin diagnosis, should replace empiric chemotherapy in patients with CUP.

Nystrom JS, Werner JM, Heffelfinger-Juttner J et al (1977) Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 4:53–58PubMed

Pentheroudakis G, Golfinopoulos V, Pavlidis N (2007) Switching benchmarks in cancer of unknown primary from autopsy to microarray. Eur J Cancer 43:2026–2036PubMedCrossRef

Greco FA, Pavlidis N (2009) Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol 100:65–74CrossRef

Hainsworth JD, Greco FA: Cancer of unknown primary site. Brawley DW, et al. eds: ACS textbook of cancer. London: John Wiley and Sims LTD, pending publication

Su AI, Welsh JB, Sapinoso LM et al (2001) Molecular classification of human carcinoma by use of gene expression signatures. Cancer Res 61:7388–7393PubMed

Golub TR, Slonim DK, Tamayo P et al (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531–537PubMedCrossRef

Talantov D, Baden J, Jatkoe T et al (2006) A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn 8:320–329PubMedCentralPubMedCrossRef

Ramaswamy S, Tamayo P, Rifkin R et al (2001) Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci USA 98:15149–15154PubMedCentralPubMedCrossRef

Bloom GC, Eschrich S, Zhou JX et al (2007) Elucidation of a protein signature discriminating six common types of adenocarcinoma. Int J Cancer 120:769–775PubMedCrossRef

10.

Penland SK, Keku TO, Torrice C et al (2007) RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest 87:383–391PubMed

11.

Shedden KA, Taylor JMG, Giordano TJ et al (2003) Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. Am J Pathol 163:1985–1995PubMedCentralPubMedCrossRef

12.

Yu J, Yu J, Almal AA et al (2007) Feature selection and molecular classification of cancer using genetic programming. Neoplasia 9:292–303PubMedCentralPubMedCrossRef

13.

Dumur CI, Lyons-Weiler M, Sciulli C et al (2008) Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J Molecular Diagn 10:67–77CrossRef

14.

Monzon FA, Lyons-Weiler M, Buturovic LJ et al (2009) Multicenter validation of a 1550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 27:2503–2508PubMedCrossRef

15.

Pillai R, Deeter R, Rigl CT et al (2011) Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed paraffin-embedded specimens. J Molecular Diagn 13:48–56CrossRef

16.

Ma XJ, Patel R, Wang X et al (2006) Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 130:465–473PubMed

17.

Erlander MG, Ma X-J, Kesty NC et al (2011) Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Molecular Diagn 13:493–503CrossRef

18.

Rosenwald S, Gilad S, Benjamin S et al (2010) Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol 23:814–823PubMedCrossRef

19.

Meiri E, Mueller WC, Rosenwald S et al (2012) A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist 17:801–812PubMedCentralPubMedCrossRef

20.

Kerr SE, Schnabel CA, Sullivan PS et al (2012) Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res 18:3592–3960CrossRef

21.

Weiss LM, Chu PG, Schroeder BE et al (2013) Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors. J Molecular Diagn 15:263–269CrossRef

22.

Kerr SE, Schnabel CA, Sullivan PS et al (2012) Use of a 92-gene molecular classifier to predict the site of origin for primary and metastatic tumors with neuroendocrine differentiation. Lab Invest 92:147A

23.

Greco FA, Spigel DR, Yardley DA et al (2010) Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist 15:500–506PubMedCentralPubMedCrossRef

24.

Greco FA, Lennington WJ, Spigel DR, Hainsworth JD (2013) Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J Natl Cancer Inst. doi:10.1093/jnci/djt099 PubMed

25.

Hainsworth JD, Spigel DR, Greco FA: Renal cell carcinoma presenting as cancer of unknown primary: diagnosis by molecular tumor profiling. J Clin Oncol 2013; 31(Suppl): Abstract e15501

26.

Greco FA, Spigel DR, Hainsworth JD: Molecular tumor profiling of poorly differentiated neoplasms of unknown primary site. J Clin Oncol 2013;31(Suppl):681 s (Abstract #11102)

27.

Tothill RW, Kowalczyk A, Rischin D et al (2005) An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 55:4031–4040CrossRef

28.

Horlings HM, Van Laar RK, Kerst J-M et al (2008) Gene expression profiling to identify histogenetic origin of metastatic adenocarcinoma of unknown primary. J Clin Oncol 26:4435–4441PubMedCrossRef

29.

Varadhachary GR, Talantov D, Raber MN et al (2008) Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26:4442–4448PubMedCrossRef

30.

Bridgewater J, Van Laar R, Floore A, Van’tVeer L (2008) Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br J Cancer 98:1425–1430PubMedCentralPubMedCrossRef

31.

Monzon FA, Medeiras F, Lyons-Weiler M, Henner WD (2010) Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test. Diagn Pathol 5:3PubMedCentralPubMedCrossRef

32.

Pentheroudakis G, Pavlidis N, Fountzilas G et al (2013) Novel microRNA-based assay demonstrates 92 % agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary. Mol Cancer 12:57PubMedCentralPubMedCrossRef

33.

Pentheroudakis G, Spector Y, Krikelis D et al (2013) Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors. Clin Exp Metastasis 30:431–439PubMedCrossRef

34.

Gamble AR, Bell JA, Ronan JE et al (1993) Use of tumor marker immunoreactivity to identify primary site of metastatic cancer. BMJ 306:295–298PubMedCentralPubMedCrossRef

35.

Brown RW, Campagna LB, Dunn JK et al (1997) Immunohistochemical identification of tumor markers in metastatic adenocarcinoma: a diagnostic adjunct in the determination of primary site. Am J Clin Pathol 107:12–19PubMed

36.

Tot T (1999) Adenocarcinoma metastatic to the liver; the value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer 85:171–177PubMedCrossRef

37.

DeYoung BR, Wick MR (2000) Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. Semin Diagn Pathol 17:184–193PubMed

38.

Dennis JL, Hvidsten TR, Wit EC et al (2005) Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 11:3766–3772PubMedCrossRef

39.

Lagendijk JH, Mullink H, VanDiest PJ et al (1999) Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. J Clin Pathol 52:283–290PubMedCentralPubMedCrossRef

40.

Park SY, Kim BH, Kim JH et al (2007) Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 131:1561–1567PubMed

41.

Oien K (2009) Pathologic evaluation of unknown primary cancer. Semin Oncol 36:8–37PubMedCrossRef

42.

Anderson GG, Weiss L (2010) Determining tissue of origin for metastatic cancers: meta-analysis and literature review of immunohistochemistry performance. Appl Immunohistochem Mol Morphol 18:3–8PubMedCrossRef

43.

Lester SC (2001) Special studies. In: Lester SC (ed) Manual of surgical pathology, 1st edn. Churchill Livingstone, Philadelphia, pp 73–74

44.

Bugat R, Bataillard A, Lesimple T et al (2003) Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 89(suppl 1):559–566

45.

Pavlidis N, Briasoulis E, Hainsworth J et al (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990–2005PubMedCrossRef

46.

Varadhachary GR, Abbruzzese JL, Lenzi R (2004) Diagnostic strategies for unknown primary cancer. Cancer 100:1776–1785PubMedCrossRef

47.

Handorf CR, Kulkarni A, Grenert JD et al (2013) A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. Am J Surg Pathol 37:1067–1075PubMedCrossRef

48.

Varadhachary GR, Spector Y, Abbruzzese J et al (2011) Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 17:4063–4070PubMedCrossRef

49.

Morawietz L, Floure A, Stark-Sloots L et al (2010) Comparison of histopathological and gene expression-based typing of cancer of unknown primary. Virchows Arch 456:23–29PubMedCrossRef

50.

Varadhachary GR, Karanth GR, Qiao S et al (2013) Carcinoma of unknown primary with gastrointestinal profile, immunohistochemistry, and survival data for this favorable subset. Int J Clin Oncol 18:226–231PubMedCrossRef

51.

Greco FA, Lennington WJ, Spigel DR et al (2012) Carcinoma of unknown primary site: outcomes in patients with a colorectal molecular profile treated with site-specific chemotherapy. J Cancer Ther 3:37–43CrossRef

52.

Hainsworth JD, Schnabel CA, Erlander MG et al (2012) A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer 11:112–118PubMedCrossRef

53.

Hainsworth JD, Rubin MS, Spigel DR et al (2012) Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute. J Clin Oncol 31:217–223PubMedCrossRef

54.

Hainsworth JD, Lennington WJ, Greco FA (2000) Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 18:632–635PubMed

55.

Tan DSW, Montoya J, Ng DS et al (2013) Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary. J Clin Oncol 31:e237–e239PubMedCrossRef

56.

Stella GM, Benvenuti S, Gramaglia D et al (2010) MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat 32:44–50PubMedCrossRef

57.

Golfinopoulos V, Pentheroudakis G, Goussia A et al (2012) Intercellular signaling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases. Ann Oncol 23(10):2725–2730PubMedCrossRef

58.

Gatalica Z, Millis S, Bender R, et al.: Molecular profiling of cancers of unknown primary site (CUP): paradigm shift in management of CUP. EJC 2011; 47(Suppl 2): Abstract LBA39

59.

Penley WC, Spigel DR, Greco FA, Hainsworth JD: Confirmation of non-small cell lung cancer diagnosis using ALK testing and genetic profiling in patients presenting with carcinoma of unknown primary site. J Clin Oncol 2013; 31(suppl): Abstract e115004

Titel: Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care
verfasst von: John D. Hainsworth
F. Anthony Greco
Publikationsdatum: 01.04.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 4/2014
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-014-1545-2

Springer Medizin

Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Morphology predicts BRAF V600E mutation in papillary thyroid carcinoma: an interobserver reproducibility study

Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma

Lipomatous tumors of the anterior mediastinum with muscle differentiation: a clinicopathological and immunohistochemical study of three cases

Lack of supportive evidence for the use of immunohistochemical staining to identify occult regional lymph node metastases in primary lung cancer

High GOLPH3 expression is associated with a more aggressive behavior of epithelial ovarian carcinoma

Multilayered epithelium at the gastroesophageal junction is a marker of gastroesophageal reflux disease: data from a prospective Central European multicenter study (histoGERD trial)

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie